These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 17047171

  • 1. Growth hormone favorably affects bone turnover and bone mineral density in patients with short bowel syndrome undergoing intestinal rehabilitation.
    Tangpricha V, Luo M, Fernández-Estívariz C, Gu LH, Bazargan N, Klapproth JM, Sitaraman SV, Galloway JR, Leader LM, Ziegler TR.
    JPEN J Parenter Enteral Nutr; 2006; 30(6):480-6. PubMed ID: 17047171
    [Abstract] [Full Text] [Related]

  • 2. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon.
    Haderslev KV, Jeppesen PB, Hartmann B, Thulesen J, Sorensen HA, Graff J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Staun M, Mortensen PB.
    Scand J Gastroenterol; 2002 Apr; 37(4):392-8. PubMed ID: 11989828
    [Abstract] [Full Text] [Related]

  • 3. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 4. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [Abstract] [Full Text] [Related]

  • 5. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
    Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ.
    J Bone Miner Res; 2004 Aug; 19(8):1221-30. PubMed ID: 15231008
    [Abstract] [Full Text] [Related]

  • 6. Transient Increased Calcium and Calcitriol Requirements After Discontinuation of Human Synthetic Parathyroid Hormone 1-34 (hPTH 1-34) Replacement Therapy in Hypoparathyroidism.
    Gafni RI, Guthrie LC, Kelly MH, Brillante BA, Christie CM, Reynolds JC, Yovetich NA, James R, Collins MT.
    J Bone Miner Res; 2015 Nov; 30(11):2112-8. PubMed ID: 25990370
    [Abstract] [Full Text] [Related]

  • 7. Short-Term Effects of Kefir-Fermented Milk Consumption on Bone Mineral Density and Bone Metabolism in a Randomized Clinical Trial of Osteoporotic Patients.
    Tu MY, Chen HL, Tung YT, Kao CC, Hu FC, Chen CM.
    PLoS One; 2015 Nov; 10(12):e0144231. PubMed ID: 26655888
    [Abstract] [Full Text] [Related]

  • 8. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 9. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW, de Nijs RN, Lems WF, Geusens PP, Laan RF, Huisman AM, Algra A, Buskens E, Hofbauer LC, Oostveen AC, Bruyn GA, Dijkmans BA, Bijlsma JW.
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [Abstract] [Full Text] [Related]

  • 10. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
    Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster E, Kreuzer S, Kainberger F, Frisch H, Geyer G, Hörl WH, Mayer G, Luger A.
    J Nephrol; 2004 May; 17(1):87-94. PubMed ID: 15151263
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults].
    Wilhelm B, Kann PH.
    Med Klin (Munich); 2004 Oct 15; 99(10):569-77. PubMed ID: 15490072
    [Abstract] [Full Text] [Related]

  • 18. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Oct 15; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 19. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ, Chesnut CH, Mallinak NJ.
    J Clin Endocrinol Metab; 1997 Jun 15; 82(6):1904-10. PubMed ID: 9177404
    [Abstract] [Full Text] [Related]

  • 20. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
    Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ.
    J Bone Miner Res; 1999 Jul 15; 14(7):1182-8. PubMed ID: 10404019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.